GGrantIndex
Sort

64,565 grants matching drug discovery

Identification of Covalent Transcriptional Dependencies in Melanoma

$697,629
Liron Bar-Peled · Massachusetts General Hospital · R01 · FY2024 · CA

Airway epithelial cytoglobin regulates nitric oxide synthase and development of primary ciliary dyskinesia and situs inversus

$697,617
Mark Thomas Gladwin · University Of Maryland Baltimore · R01 · FY2025 · HL

Discovering the essential genome of Plasmodium falciparum

$697,594
John Adams · University Of South Florida · R01 · FY2018 · AI

Clinical Informatics to Advance Epidemiology and Pharmacogenetics of Serious Cutaneous Adverse Drug Reactions

$697,549
Li Zhou · Brigham And Women'S Hospital · R01 · FY2021 · AI

Computational and functional discovery of isoforms driving cancer and drug resistance

$697,535
Angela Norie Brooks · University Of California Santa Cruz · R01 · FY2024 · CA

Design and development of HDAC11-specific chemical inhibitors for disease treatments

$697,517
Edward Seto · George Washington University · R01 · FY2023 · AI

Design and development of HDAC11-specific chemical inhibitors for disease treatments

$697,517
Edward Seto · George Washington University · R01 · FY2024 · AI

Design and development of HDAC11-specific chemical inhibitors for disease treatments

$697,517
Edward Seto · George Washington University · R01 · FY2022 · AI

Preclinical optimization of a parasiticidal drug for cryptosporidiosis

$697,491
Christopher D Huston · University Of Vermont & St Agric College · R01 · FY2022 · AI

Leadership, Planning, and Evaluation

$697,412
Stanton L Gerson · Case Western Reserve University · P30 · FY2020 · CA

Nomethiazoles harnessing GABA and NO mimetic activity for Alzheimer's therapy

$697,279
Gregory R J Thatcher · Revivo Therapeutics, Inc. · R42 · FY2017 · AG

Rational design and synthesis of small molecule inhibitors targeting unique pathogenic mechanisms in Gram- and Gram+ bacteria important in UTI

$697,215
James W Janetka · Washington University · U19 · FY2025 · AI

Antagonists of A2B Receptors Improve Insulin Sensitivity

$697,156
Adenosine Therapeutics, Llc · R44 · FY2005 · DK

Development of Novel Inhibitors of Ganglioside Biosynthesis

$697,057
Brett E Crawford · Zacharon Pharmaceuticals, Inc. · R44 · FY2008 · CA

Selective inhibitors of MLCL/CytC Peroxidase in Barth Syndrome

$697,006
Valerian E Kagan · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · HL

Identification of small molecules for neurological complications of HIV and substance abuse comorbidity

$696,944
Pietro P Sanna · Scripps Research Institute, The · R01 · FY2018 · DA

Developing Immunotherapeutics for Methamphetamine Abuse

$696,926
Thomas Richard Kosten · Baylor College Of Medicine · U01 · FY2009 · DA

Epigenetic Probes for HMTs

$696,840
Haiching Ma · Reaction Biology Corporation · R44 · FY2016 · TR

Drug repurposing of a novel synthetic progestin for the prevention of preterm labor and fetal inflammation

$696,840
Suhas Kallapur · University Of California Los Angeles · R01 · FY2024 · HD

Propargyl-linked Antifolates Targeting Klebsiella pneumoniae

$696,770
Dennis L Wright · University Of Connecticut Storrs · R01 · FY2017 · AI

Molecular Roles of Cdk5 in Neuronal Functions and Pain Signaling

$696,702
Ashok Kulkarni · National Institute Of Dental & Craniofacial Research · ZIA · FY2010 · DE

UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program

$696,677
Kim L Brouwer · Univ Of North Carolina Chapel Hill · T32 · FY2018 · GM

COMPARATIVE GENOMICS OF PARASITIC NEMATODES

$696,640
Makedonka Mitreva · Washington University · R56 · FY2019 · AI

Integrated ligand and target discovery by chemical proteomics for glioblastoma treatment.

$696,619
Paul S Mischel · Stanford University · R01 · FY2021 · CA

Vascular Stiffness as a Precursor of Hypertension in a Middle-aged Cohort

$696,589
Vasan S. Ramachandran · Boston University Medical Campus · R01 · FY2015 · HL